Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
62people in the Metformin in Insulin Resistant LV Dysfunction, a Double-blind, Placebo-controlled Trial trial, from 2007
of them with type 2 diabetes, in this paper
Already taking metformin, or nottheir own situation, not assigned
on metformin
sulfonylurea
Metformin went with higher likelihood that neutrophil to lymphocyte ratio would be lower than baseline1.8×
correlation, not a testthe abstract, start to end
… lymphocyte ratio after 8 to 16 months by 0.09 U (95% confidence interval, 0.02-0.17; P=0.013) and increased the likelihood that neutrophil to lymphocyte ratio would be lower than baseline after 8 to 16 months (odds ratio, 1.83; 95% confidence interval, …
← favours treatmentfavours comparator →
could be chanceMean log-transformed neutrophil to lymphocyte ratiometformin vs sulfonylurea, in nondiabetic diabetes mellitus population
−0.09−0.17 to −0.02
Likelihood that neutrophil to lymphocyte ratio would be lower than baselinemetformin vs sulfonylurea, in nondiabetic diabetes mellitus population
OR 1.831.22–2.75
MetforminAdverse events & safety
1 / 4